Gab1 adaptor protein acts as a gatekeeper to balance hepatocyte death and proliferation during acetaminophen‐induced liver injury in mice

Kunimaro Furuta, Yuichi Yoshida, Satoshi Ogura, Tomohide Kurahashi, Takashi Kizu, Shinichiro Maeda, Mayumi Egawa, Norihiro Chatani, Keigo Nishida, Yoshikazu Nakaoka, Shinichi Kiso, Yoshihiro Kamada, Tetsuo Takehara – 17 December 2015 – Acetaminophen (APAP) overdose is the leading cause of drug‐induced acute liver failure. In APAP‐induced acute liver failure, hepatocyte death and subsequent liver regeneration determines the prognosis of patients, making it necessary to identify suitable therapeutic targets based on detailed molecular mechanisms.

Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B−/− (Wilson disease) mice

James P. Hamilton, Lahari Koganti, Abigael Muchenditsi, Venkata S. Pendyala, David Huso, Joseph Hankin, Robert C. Murphy, Dominik Huster, Uta Merle, Christopher Mangels, Nan Yang, James J. Potter, Esteban Mezey, Svetlana Lutsenko – 17 December 2015 – Wilson disease (WD) is a hepatoneurological disorder caused by mutations in the copper‐transporter, ATP7B. Copper accumulation in the liver is a hallmark of WD. Current therapy is based on copper chelation, which decreases the manifestations of liver disease, but often worsens neurological symptoms.

Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B−/− (Wilson disease) mice

James P. Hamilton, Lahari Koganti, Abigael Muchenditsi, Venkata S. Pendyala, David Huso, Joseph Hankin, Robert C. Murphy, Dominik Huster, Uta Merle, Christopher Mangels, Nan Yang, James J. Potter, Esteban Mezey, Svetlana Lutsenko – 17 December 2015 – Wilson disease (WD) is a hepatoneurological disorder caused by mutations in the copper‐transporter, ATP7B. Copper accumulation in the liver is a hallmark of WD. Current therapy is based on copper chelation, which decreases the manifestations of liver disease, but often worsens neurological symptoms.

Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy

Christophe Cassinotto, Jérome Boursier, Victor de Lédinghen, Jérome Lebigot, Bruno Lapuyade, Paul Cales, Jean‐Baptiste Hiriart, Sophie Michalak, Brigitte Le Bail, Victoire Cartier, Amaury Mouries, Frédéric Oberti, Isabelle Fouchard‐Hubert, Julien Vergniol, Christophe Aubé – 13 December 2015 – Nonalcoholic fatty liver disease (NAFLD) has become a major public health issue.

Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma

Chuan‐chuan Zhou, Fu Yang, Sheng‐xian Yuan, Jin‐zhao Ma, Feng Liu, Ji‐hang Yuan, Feng‐rui Bi, Kong‐ying Lin, Jian‐hua Yin, Guang‐wen Cao, Wei‐ping Zhou, Fang Wang, Shu‐han Sun – 13 December 2015 – Systemic analyses using large‐scale genomic profiles have successfully identified cancer‐driving somatic copy number variations (SCNVs) loci. However, functions of vast focal SCNVs in “protein‐coding gene desert” regions are largely unknown.

Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study

Marta Cavallin, Salvatore Piano, Antonietta Romano, Silvano Fasolato, Anna Chiara Frigo, Gianpiero Benetti, Elisabetta Gola, Filippo Morando, Marialuisa Stanco, Silvia Rosi, Antonietta Sticca, Umberto Cillo, Paolo Angeli – 13 December 2015 – In patients with cirrhosis and hepatorenal syndrome (HRS), terlipressin has been used either as continuous intravenous infusion or as intravenous boluses. To date, these two approaches have never been compared.

Subscribe to